Discover PsA

Reference List

  1. Husted JA, Tom BD, Farewell VT, et al. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: Does the effect change over time? Arthritis Rheum. 2007;56(3):840‑849.
  2. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42(12):1460‑1468.
  3. Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005;64(2):188‑190.
  4. Yamamoto T. Psoriatic arthritis: from a dermatological perspective. Eur J Dermatol. 2011;21(5):660‑666.
  5. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851‑864.
  6. National Psoriasis Foundation. Diagnosing psoriatic arthritis. http://www.psoriasis.org/ psoriatic‑arthritis/diagnosis. Accessed September 16, 2013.
  7. Boehncke WH, Adebajo A, Cauli A, et al. Initiative for quality in psoriasis and psoriatic arthritis. J Rheumatol. 2008 Jul;35(7):1431‑1433.
  8. Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72:736–740.
  9. Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T. 2010;35(12):680‑689.
  10. Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States. JAMA Dermatol. doi:10.1001/jamadermatol.2013.5264.
  11. Gottlieb AB, Mease PJ, Mark Jackson J, et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. J Dermatolog Treat. 2006;17(5):279‑287.
  12. Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther. 2009;11(1):214.
  13. Gladman DD. Psoriatic arthritis. Dermatol Ther. 2009 Jan‑Feb;22(1):40‑55.
  14. Pattison E, Harrison BJ, Griffiths CE, et al. Environmental risk factors for the development of psoriatic arthritis: results from a case‑control study. Ann Rheum Dis. 2008;67(5):672‑676.
  15. Eder L, Law T, Chandran V, et al. Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res (Hoboken). 2011;63(8):1091‑1097.
  16. Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55‑78.
  17. Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PSA)—an analysis of 220 patients. Q J Med. 1987 Feb;62(238):127‑141.
  18. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol. 1991 Aug;30(4):245‑250.
  19. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis. 2005;64(suppl 2):ii3‑ii8.
  20. Fitzgerald O. Psoriatic arthritis. In: Firestein GS, et al. Kelley's Textbook of Rheumatology. 8th ed. Philadelphia, PA: WB Saunders Co; 2008.
  21. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777‑783.
  22. Altman RD. Rheumatoid arthritis (RA). The Merck Manual for Healthcare Professionals. http://www.merckmanuals.com/ home/bone_joint_and_muscle_disorders/ joint_disorders/rheumatoid_arthritis_ra.html?qt=rheumatoid arthritis&alt=sh. Updated May 2013. Accessed September 12, 2013.
  23. Vandooren B, Noordenbos T, Ambarus C, et al. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum. 2009 Apr;60(4):966‑75.
  24. Brodszky V, Balint P, Geher P, et al. Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int. 2009;30(2):199–205.
  25. Huscher D, Merkesdal S, Thiele K, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis..2006;65(9):1175‑1183.
  26. Singh JA, Strand V. Health care utilization. Rheumatology. 2009;48:272‑276.
  27. Singh JA, Strand V. Spondyloarthritis is associated with poor function and physical health‑related quality of life. J Rheumatol. 2009;36;1012‑1020.
  28. Tillett W, de‑Vries C, McHugh NJ. Work disability in psoriatic arthritis: a systematic review. Rheumatology. 2012;51:275‑283.
  29. Husted JA, Thavaneswaran A, Chandran V, Gladman DD. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol. 2013;40(8):1349‑56.
  30. Zhang F, Gauthier G, Hiscock R, Curtis J. Treatment patterns in psoriatic arthritis patients newly initiated on non‑biologic disease‑modifying anti‑rheumatic drugs. Presented at the 12th Annual Meeting of the ACR/ARHP. November 10‑14, 2012; Washington, DC.
  31. Zhang F, Li S, Curtis JR. United States treatment patterns in psoriatic arthritis newly initiated on etanercept or adalimumab. Presented at the 15th Annual European Conference of ISPOR. November 3‑7, 2012; Berlin, Germany.
  32. Bäumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007;6:17‑26.
  33. Souness JE, Griffin M, Maslen C, et al. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low‑affinity' phosphodiesterase 4 conformer. Br J Pharmacol. 1996;118:649‑658.
  34. Ma R, Yang BY, Wu CY. A selective phosphodiesterase 4 (PDE4) inhibitor Zl‑n‑91 suppresses IL‑17 production by human memory Th17 cells. Int Immunopharmacol. 2008;8:1408‑1417.
  35. Oger S, Mehats C, Dallot E, et al. Evidence for a role of phosphodiesterase 4 in lipopolysaccharide‑stimulated prostaglandin E2 production and matrix metalloproteinase‑9 activity in human amniochorionic membranes. J Immunol. 2005;174:8082-8089.
  36. Van Parijs L, Abbas AK. Homeostasis and self‑tolerance in the immune system: turning lymphocytes off. Science. 1998;280:243‑248.
  37. Taskén K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev. 2004;84:137‑167.
  38. van Kuijk AW, Reinders‑Blankert P, Smeets TJ, et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006;65:1551‑1557.
Fold image
corner image

Receive Email Updates & Additional Information

Sign-up Now »
Fold image
corner image
Fold image
corner image